192 related articles for article (PubMed ID: 31218849)
21. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
[TBL] [Abstract][Full Text] [Related]
22. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory.
Hui L; Rixv L; Xiuying Z
Clin Biochem; 2015 Dec; 48(18):1241-5. PubMed ID: 26216289
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
24. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
25. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY
Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883
[TBL] [Abstract][Full Text] [Related]
26. Neuron-Specific Enolase and Hemoglobin as Risk Factors of Intraocular Metastasis in Patients with Renal Cell Carcinoma.
Li QY; Su T; Shi WQ; Fang JW; Zhang MY; Xu QH; Liang RB; Ge QM; Li B; Shao Y
Dis Markers; 2022; 2022():2883029. PubMed ID: 35502301
[TBL] [Abstract][Full Text] [Related]
27. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
28. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
[TBL] [Abstract][Full Text] [Related]
29. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments.
Buccheri G; Torchio P; Ferrigno D
Chest; 2003 Aug; 124(2):622-32. PubMed ID: 12907552
[TBL] [Abstract][Full Text] [Related]
30. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
[TBL] [Abstract][Full Text] [Related]
31. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
[TBL] [Abstract][Full Text] [Related]
32. Cytokeratin-19 fragment in the diagnosis of bladder carcinoma.
Guo XG; Long JJ
Tumour Biol; 2016 Oct; 37(10):14329-14330. PubMed ID: 27448817
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance and prognostic value of pentraxin-3 as serologic biomarker for lung cancer.
Zhang D; Ren WH; Gao Y; Wang NY; Wu WJ
Asian Pac J Cancer Prev; 2013; 14(7):4215-21. PubMed ID: 23991979
[TBL] [Abstract][Full Text] [Related]
34. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer.
Kosacka M; Jankowska R
Pol Arch Med Wewn; 2009; 119(1-2):33-7. PubMed ID: 19341176
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of serum DJ-1 in lung adenocarcinoma.
Wang L; Wei L; Miao S; Zhang W
PeerJ; 2024; 12():e16845. PubMed ID: 38304191
[TBL] [Abstract][Full Text] [Related]
36. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
37. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
[TBL] [Abstract][Full Text] [Related]
39. Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.
Sertić Milić H; Franjević A; Bubanović G; Marušić A; Nikolić I; Puljić I
Wien Klin Wochenschr; 2015 Jun; 127(11-12):465-71. PubMed ID: 25917364
[TBL] [Abstract][Full Text] [Related]
40. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]